Summit Therapeutics (Summit Therapeutics) Interest Expense : $-16.46 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Summit Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Summit Therapeutics's interest expense for the three months ended in Dec. 2023 was $ -2.90 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-16.46 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Summit Therapeutics's Operating Income for the three months ended in Dec. 2023 was $ -36.25 Mil. Summit Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $ -2.90 Mil. Summit Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Summit Therapeutics Interest Expense Historical Data

The historical data trend for Summit Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics Interest Expense Chart

Summit Therapeutics Annual Data

Trend

Jan14

Jan15

Jan16

Jan17

Jan18

Jan19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.62

-0.26

-0.24

-4.40

-16.46

Summit Therapeutics Quarterly Data
	Jan19	Apr19	Jul19	Oct19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-2.90	-8.33	-2.52	-2.72	-2.90

Summit Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.46 Mil.

Summit Therapeutics (NAS:SMMT) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Summit Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $-2.90 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-36.25 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $103.29 Mil.

Summit Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Summit Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Summit Therapeutics (Summit Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics Inc (NAS:SMMT) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025

Website

https://www.smmttx.com

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Executives

Ankur Dhingra	officer: Chief Financial Officer	C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Maky Zanganeh	director	51 ADAM WAY, ATHERTON CA 94027
Manmeet Singh Soni	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Robert W Duggan	director, 10 percent owner, officer: See Remarks	611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Yu Xia	director	6 SHENNONG ROAD, TORCH DEVELOPMENT ZONE, ZHONGSHAN, GUANGDONG F4 528437
Robert F. Booth	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Alessandra Cesano	director	700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Urte Gayko	director	C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Kenneth A Clark	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Jeffrey R Maranian	officer: VP, Corporate Controller	C/O SUMMIT THERAPEUTICS INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Luhua Wang	director	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
David Jonathan Powell	officer: Chief Scientific Officer	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Camilla Graham	officer: Chief Clinical Affairs Officer	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ventzislav Stefanov	director, officer: See Remarks	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ujwala Mahatme	director	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142